IP Library Granted Patent US 9,290,581
Granted Patent B2
US 9,290,581 · App. 14/139,440 · Granted Mar 22, 2016

Immobilized proteins and methods and uses thereof

Inventors: Charles Dale Poulter (Park City, UT); Guillermo Roberto Labadi (Rasario, AR); Cecile Gauchet (Balma, FR); Rochelle Frances Hawkins Bohaty (Salt Lake City, UT)
Assignee: University of Utah Research Foundation
C07K17/14C07K1/1077C07K1/1133C07K14/00C07K14/43595C12N9/1088C12P21/00G01N33/54393G01N33/552
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,290,581
App. No.
14/139,440
Granted
Mar 22, 2016
Kind
B2
Abstract

The invention relates to the field of covalently attaching proteins to a substrate, particularly to methods of immobilizing proteins by posttranslationally modifying a cysteine residue of said protein through the addition of functional groups. The invention also relates to biological molecules used in such techniques, including proteins, and detection methods and kits that utilize such immobilized proteins, such as a microdevice or “protein chip”, a high-throughput screening device, and for the microscopy of proteins on a surface.

Claims (19)

1. A method of covalently immobilizing a protein, comprising:

a. posttranslationally modifying a cysteine residue of said protein through the addition of functional groups, and

b. immobilizing said protein by ligation of said functional groups to a substrate;

wherein said protein comprises a soluble protein or a solubilized protein, and wherein said substrate comprises one or more of an azide-derivatized surface and an alkyne-derivatized surface.

2. The method of claim 1 , wherein said cysteine is in a C-terminal CaaX motif of a soluble protein.

3. The method of claim 2 , where X is A, S, M, L or Q.

4. The method of claim 1 , wherein said posttranslational modification of a cysteine includes alkylation of the sulthydryl moiety comprising one or more of catalysis of a farnesyl analog with protein farnesyltransferase and catalysis of a geranylgeranyl analog with protein geranylgeranyltransferase.

5. The method of claim 4 , where said functional group comprises one or more of an azide, an alkyne, an alkene, a ketone and an alkoxyamine.

6. The method of claim 4 , wherein said farnesyl analog is selected from the analogs depicted in FIG. 9 .

7. The method of claim 1 , wherein said functional group comprises one or more of an azide and an alkyne.

8. The method of claim 1 , wherein said substrate comprises one or more of a silicon surface selected from the group consisting of silicon, glass, SiO 2 , and silicon nitride, a polymer surface comprising one or more of polymer beads and polymer films, a gel surface comprising one or more of an agarose gel and an acrylamide gel, and a metal surface comprising one or more of platinum, gold, silver, copper, zinc sulfide, cadmium selenide, zinc sulfide-capped cadmium selenide, titanium dioxide, aluminum, aluminum oxide, opal films, and ceramics.

9. The method of claim 8 , wherein said substrate comprises one or more of an azide-derivatized glass surface and an alkyne-derivatized glass surface.

10. A method of covalently immobilizing a protein, comprising:

a. alkylating the sulthydryl moiety in a C-terminal CaaX motif of a protein through a catalysis selected from the group consisting of catalysis of a farnesyl analog with protein farnesyltransferase and catalysis of a geranylgeranyl analog with protein geranylgeranyltransferase, resulting in the addition of a functional group, and

b. immobilizing the derivatized protein of (a) to a substrate comprising one or more of an azide-derivatized surface and an alkyne-derivatized surface;

wherein said protein comprises one or more of a soluble protein and a solubilized protein.

11. The method of claim 10 , where X is A, S, M, L or Q.

12. The method of claim 10 , where said functional group comprises one or more of an azide, an alkene, an alkyne, a ketone, or an alkoxyamine.

13. The method of claim 10 , wherein said farnesyl analog is selected from the analogs depicted in FIG. 9 .

Assignments (3)
CONFIRMATORY LICENSE Recorded Sep 28, 2016
From: UNIVERSITY OF UTAH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040167/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2016
From: POULTER, CHARLES DALE; LABADIE, GUILLERMO ROBERTO; GAUCHET, CECILE; HAWKINS BOHATY, ROCHELLE FRANCES
To: UNIVERSITY OF UTAH
Reel/Frame 037730/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2016
From: UNIVERSITY OF UTAH
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 037730/0436 →
Continuity (4)
Division 13482512 · May 29, 2012
Continuation 12225359
Provisional Application 60785249 · Mar 22, 2006
Related Publication 20140378670A1 · Dec 25, 2014